Updated on: November 28, 2016

New Technology Equals Additional Reimbursement

By
Original story posted on: February 15, 2016

Today, February 16, the Centers for Medicare & Medicaid Services (CMS) is holding a New Technology Town Hall Meeting at the CMS Headquarters in Baltimore.

The New Technology meeting is being held to allow the agency to review applications for New Technology designation in the Medicare Severity-Diagnosis Related Groups (MS-DRGs) reimbursement methodology for the Inpatient Prospective Payment System (IPPS). This designation is important for hospitals as it means the potential for additional reimbursement. During the 2016 fiscal year, the additional reimbursement ranged from $1,000 to $72,000 per case.

New technology add-on payments were created to ensure that hospitals were adequately compensated for new devices and/or procedures. The criteria for new technology includes requirements that the medical service or technology be new (within 2-3 years), that it demonstrates significant clinical improvement, that it has gained approval by the Federal Drug Administration (FDA), and that it can be identified by CPT, HCPCS, National Drug Code, or ICD-10-PCS (formerly ICD-9-CM Volume 3) codes.

The Town Hall meeting will focus on the 2016 New Technology designations and determine if they should continue. These 2016 technologies included:

  1. Argus II Retinal Prosthesis System: a device used to treat retinitis pigmentosa that had a potential additional reimbursement of $72,028.75.
  2. Cardio-MEMS HF Monitoring System: a device used to treat heart failure that had a potential additional reimbursement of $8,875.
  3. MitraClip: a device used to treat mitral valve regurgitation that had a potential additional reimbursement of $15,000.
  4. Responsive Neurostimulator (RNS) System: a device used to treat epilepsy that had a potential additional reimbursement of $18, 475.
  5. BLINCYTO (Blinatumomab): a substance used to treat acute lymphoblastic leukemia that had potential additional reimbursement of $27.017.15 based on a 17-day treatment cycle.
  6. Lutonix Drug Coated Balloon (DCB) for PTA: a device used to treat peripheral artery disease that had a potential additional reimbursement of $1,035.72.

BLINCYTO and the Lutonix Drug Coated Balloon were new in 2016. The first four items are in danger of being discontinued for 2017. A new technology/service cannot maintain the designation for longer than three years. The IPPS Final Rule for 2017 will contain the final determinations, but we will get a glimpse of the decisions sometime in April or May.

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.
Laurie M. Johnson, MS, RHIA, FAHIMA AHIMA Approved ICD-10-CM/PCS Trainer

Laurie M. Johnson, MS, RHIA, FAHIMA, AHIMA Approved ICD-10-CM/PCS Trainer is currently a senior healthcare consultant for Revenue Cycle Solutions, based in Pittsburgh, Pa. Laurie is an American Health Information Management Association (AHIMA) approved ICD-10-CM/PCS trainer. She has more than 35 years of experience in health information management and specializes in coding and related functions. She has been a featured speaker in over 40 conferences. Laurie is a member of the ICD10monitor editorial board and makes frequent appearances on Talk Ten Tuesdays.

Related Stories

  • COVID-19: To query or not to query; to report or not to report?
    According to the official coding guidelines, ICD-10 code U07.1 for COVID-19 may be reported under the following circumstances: As documented by the provider; Documentation of a positive COVID-19 test result; or A presumptive positive COVID-19 test result. “Presumptive” was the…
  • COVID-19 Coding Dilemma: Z20.828 and Z03.818
    ICD-10-CM codes are not robust enough to tell the patient story correctly.   I was having a terrible time preparing for my COVID-19 coding webinar, held on the afternoon of April 29, because the current ICD-10-CM codes under the current…
  • We now Have a Code for COVID-19; Here’s How to use it Correctly
    The patient has COVID-19? How is the infection manifesting? You need a code for that detail. The rapidity with which our medical world is evolving is unbelievable. I know that aiming for optimal documentation is a worthy goal, but I…